<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106738</url>
  </required_header>
  <id_info>
    <org_study_id>Policlinic hospital, 9</org_study_id>
    <nct_id>NCT05106738</nct_id>
  </id_info>
  <brief_title>Phase Angle and Chronic Intestinal Inflammatory Diseases</brief_title>
  <acronym>PHIBO</acronym>
  <official_title>Phase Angle as a New Possible Prognostic Factor in Chronic Intestinal Inflammatory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase angle (PhA) is a biometric parameter measured by bioimpedance analysis (BIA), which&#xD;
      reflects organism cellularity and tissues hydration. In addition, since it correlates with&#xD;
      the presence of inflammation and the nutritional status, it could be useful to monitor&#xD;
      inflammatory bowel disease (IBD) activity. The aim of this study was to establish the&#xD;
      potential use of PhA as a new non-invasive and sensitive marker correlated with mucosal&#xD;
      healing and/or IBD activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, fecal calprotectin is considered the best indirect marker inversely correlated&#xD;
      with the mucosal healing in patients with inflammatory bowel disease (IBD). C reactive&#xD;
      protein (CRP), is less reliable than fecal calprotectin in the evaluation of IBD activity. In&#xD;
      order to establish the potential use of phase angle (PhA) as a new non-invasive and sensitive&#xD;
      marker of mucosal healing and/or disease activity in patients with IBD, patients with&#xD;
      diagnosis of chronic inflammatory bowel diseases (IBD) according to the European Crohn's and&#xD;
      Colitis Organization (ECCO) guidelines will be enrolled. In these patients, the following&#xD;
      parameters will be evaluated: age, sex, body mass index (BMI), percentage of weight loss in&#xD;
      the last 6 months, duration of illness, location of disease, any previous intestinal surgery,&#xD;
      ongoing therapy for IBD, activity disease by clinical scores, CRP, fecal calprotectin,&#xD;
      disease activity by endoscopic scores, PhA and fat free mass (FFM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The correlation of phase angle with mucosal healing in patients with inflammatory bowel disease</measure>
    <time_frame>At enrollment</time_frame>
    <description>The evaluation of phase angle (PhA), expressed in degrees, will be obtained by bioimpedenziometry, using a specific software (Bodygram Pro 3.0, Akern srl, Pontassieve, Italy). The assessment of mucosal healing will be performed by the following endoscopic scores: the Simple Endoscopic Score for Crohn's Disease (SES-CD) and the Mayo endoscopic score for Crohn's disease and Ulcerative Colitis (UC), respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the presence of malnutrition by bioimpedance analysis</measure>
    <time_frame>At enrollment</time_frame>
    <description>Malnutrition will be assessed by the evaluation of body composition [fat free mass (FFM) and fat mass (FM) expressed in kg], by bioimpedance analysis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Mucosal Inflammation</condition>
  <condition>Leukocyte L1 Antigen Complex</condition>
  <condition>C-Reactive Protein</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Crohn's disease and patients with Ulcerative Colitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histological report confirming the diagnosis of IBD,&#xD;
&#xD;
          -  value of C-reactive protein (CRP)&#xD;
&#xD;
          -  fecal calprotectin,&#xD;
&#xD;
          -  colonoscopy within 3 months from the enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of ascites or edema,&#xD;
&#xD;
          -  chronic or autoimmune inflammatory diseases,&#xD;
&#xD;
          -  ongoing infections,&#xD;
&#xD;
          -  recent surgery (in the last 6 months),&#xD;
&#xD;
          -  neoplastic diseases,&#xD;
&#xD;
          -  ongoing enteral or parenteral nutrition,&#xD;
&#xD;
          -  presence of fistulae,&#xD;
&#xD;
          -  ileostomy or colostomy,&#xD;
&#xD;
          -  short bowel syndrome,&#xD;
&#xD;
          -  pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michele Barone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Barone, MD</last_name>
    <phone>011-39-3477157666</phone>
    <email>michele.barone@uniba.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Michele Barone</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Barone, MD</last_name>
      <phone>3477157666</phone>
      <email>michele.barone@uniba.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Michele Barone</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

